Koers Onconova Therapeutics Inc Nasdaq
Aandelen
US68232V3069
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 210K 193K | Omzet 2025 * | 300K 276K | Marktkapitalisatie | 13,49 mln. 12,42 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,17 mln. | Nettowinst (verlies) 2025 * | -28 mln. -25,77 mln. | EV/omzet 2024 * | 64,2 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 45 x |
K/w-verhouding 2024 * |
-0,74
x | K/w-verhouding 2025 * |
-0,77
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,39% |
Recentste transcriptie over Onconova Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19-01-15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01-09-13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01-07-15 |
Jack Stover
BRD | Director/Board Member | 69 | 23-05-16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01-04-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,79% | 54,04 mld. | |
-0,56% | 41,92 mld. | |
+49,62% | 41,96 mld. | |
-7,20% | 28,35 mld. | |
+12,59% | 26,35 mld. | |
-21,51% | 19 mld. | |
+6,92% | 13 mld. | |
+24,91% | 12,19 mld. | |
+29,60% | 12,28 mld. |